ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1402	National Cancer Institute	Html	en	Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.	T-cell lymphoblastic lymphoma 0.616756 mediastinal B-cell lymphoma 0.654258 Pediatric Non-Hodgkin Lymphoma 0.567507 mature B-cell 0.675642 Engl J Med 0.525188 B-cell non-Hodgkin lymphoma 0.746462 children 0.65412 mature B-cell leukemia 0.544897 cell lymphoma outcome 0.543686 lymphoblastic lymphoma stage 0.540387 pediatric-type follicular lymphoma 0.574777 large B-cell lymphomas 0.528398 large cell lymphoma 0.779097 pediatric anaplastic lymphoma 0.540067 adolescents 0.539146 Burkitt lymphoma 0.638477 mediastinal large B-cell 0.573557 childhood B-cell non-Hodgkin 0.52722 diffuse large b-cell 0.665879 anaplastic large-cell lymphoma 0.616485 center-derived B-cell lymphoma 0.609426 Burkitt lymphoma incidence 0.577758 cell lymphoma cases 0.534062 Leuk Lymphoma 0.529329 large B-cell lymphoma 0.815777	cell lymphoma patients 0.528087 mature B-cell lymphoma 0.609056 et al. 0.801373 Br J Haematol 0.629196 Cairo MS 0.571856 primary mediastinal B-cell 0.5557 Pediatr Blood Cancer 0.817055 childhood B-cell 0.532059 diffuse large-B-cell lymphoma 0.523303 Secondary non-Hodgkin lymphoma 0.572995 mature B-cell non-Hodgkin 0.643468 lymphoblastic lymphoma 0.618923 Abstract 0.750082 cancer group 0.553869 lymphoma 0.902345 Clin Oncol 0.644225 childhood non-Hodgkin lymphoma 0.549011 high-stage Burkitt lymphoma 0.543865 B-cell lymphoma subgroups 0.565819 non-hodgkin lymphoma 0.766463 recurrent non-Hodgkin lymphoma 0.543912 anaplastic large cell 0.660109 oncology group 0.53775 Burkitt-like lymphoma 0.528197	CLICK HERE
1431	National Cancer Institute	Html	en	Prostate Cancer Prevention (PDQ®)–Patient Version	Expert-reviewed information summary about factors that may influence the risk of developing prostate cancer and about research aimed at the prevention of this disease.	cancer risk factors 0.382888 cancer treatment 0.345379 cancer prevention trials 0.393424 prostate cancer prevention 0.528023 cancer protective factor 0.370188 prostate gland 0.401353 Prostate Cancer Events 0.438643 protective factors 0.37428 Cancer Information Service 0.363767 following PDQ summaries 0.363098 PDQ cancer information 0.439164 advanced prostate cancer 0.435515 high-grade prostate cancer 0.447263 Clinical Trials section 0.34275 prevention clinical trials 0.365763 male sex 0.35549 white men 0.343088 men 0.418793 Prevention Editorial Board 0.367822 treatment clinical trials 0.342421 National Cancer Institute 0.410797 clinical trials 0.465084 folic acid 0.367544	cancer information summary 0.404534 fewer prostate cancers 0.434955 Vitamin E Cancer 0.36527 new treatment 0.346999 localized prostate cancer 0.435368 breast cancer prevention 0.361722 Cancer Prevention Trial 0.41435 prostate cancer increases 0.444676 prostate cancer risk 0.48237 cancer patients 0.343751 Cancer Care page 0.358977 cancer risk factor 0.385548 NCI’s PDQ 0.343309 normal prostate growth 0.414243 PDQ summary 0.356651 aggressive prostate cancers 0.429295 NCI PDQ cancer 0.383175 prostate cancer 0.982122 bigger prostate 0.40149 cancer clinical trials 0.368698 risk factors 0.422068 cancer information summaries 0.367063 comprehensive cancer information 0.367142	CLICK HERE
1452	National Cancer Institute	Html	en	Cigarette Smoking: Health Risks and How to Quit (PDQ®)–Health Professional Version	Expert-reviewed information summary about research and guidelines focused on the prevention and cessation of cigarette smoking.	smoking cessation strategy 0.633721 smoking cessation rates 0.605741 quit attempt 0.552085 effective smoking cessation 0.580922 gradual cessation group 0.483049 abrupt cessation 0.562882 prolonged validated smoking 0.480554 lung cancer 0.658405 tobacco cessation 0.463262 smoking cessation pharmacotherapies 0.597527 abrupt smoking cessation 0.601297 pipe tobacco smoking 0.505275 current smoking 0.475722 gradual cessation arm 0.465437 nicotine replacement therapy 0.54532 randomized trial 0.492165 Smoking cessation counseling 0.609156 receptor partial agonist 0.460896 area-level smoking prevalence 0.513667 smoking reduction 0.49426 smoking behavior 0.469981 smoking cessation treatment 0.588411 smoking prevalence data 0.513642 tobacco products 0.485537	abrupt cessation arm 0.472163 smoking cessation 0.926558 vs abrupt cessation 0.475821 adult cigarette smoking 0.474818 gradual cessation method 0.466403 cigarette smoking cessation 0.573293 cigarette smoking 0.62168 smoking cessation pharmacotherapy 0.595082 varenicline 0.542592 tobacco smoking 0.505702 smoking cessation rate. 0.602815 gradual cessation 0.501212 abrupt cessation group 0.489713 nicotinic acetylcholine receptor 0.464069 self-reported smoking abstinence 0.502629 smoking abstinence 0.574891 cigarette smoking prevalence 0.566333 randomized controlled trial 0.482431 6-month cessation rates 0.474432 nicotine patch 0.531368 smoking cessation intervention 0.590903 usual smoking patterns 0.480697 lung cancer mortality 0.510576 varenicline group 0.534998	CLICK HERE
1682	National Cancer Institute	Html	en	Family Caregivers in Cancer: Roles and Challenges (PDQ®)–Health Professional Version	Expert-reviewed information summary about the challenges faced by family caregivers of cancer patients. This summary focuses on typical caregiver roles and concerns, and helpful interventions for caregivers.	caregiver strain 0.637562 caregiver self-efficacy 0.583778 caregiver involvement 0.610915 cancer care facility 0.578352 palliative care consultation 0.608288 caregiver knowledge 0.586068 Hispanic caregivers 0.676204 caregiver 0.821035 Caregiver quality 0.603509 white caregivers 0.639176 health care providers 0.59721 specialist-level palliative care 0.56948 caregiver well-being 0.592799 patient symptom care 0.583377 culturally competent care 0.564531 patients 0.715455 cancer patients 0.703941 Asian American caregivers 0.689382 caregiver emotional health 0.625075 secondary informal caregivers 0.653486 caregiver burden 0.63516 caregiver’s information 0.595277 symptom management 0.696609 orient caregivers 0.633121 primary caregiver 0.613245	caregiver portion 0.581896 African American caregivers 0.664952 caregiver needs 0.592313 end-of-life care 0.586635 family caregivers 0.726566 study 0.578902 problem-solving intervention 0.564815 bereaved caregivers 0.642182 palliative care 0.6279 tailored caregiver interventions. 0.613747 African American patients 0.595756 caregivers 0.977146 terminally ill patients 0.564522 studies 0.568233 empowers caregivers 0.628512 caregiver roles 0.620453 minority caregivers 0.663649 emotional support 0.572233 home care workers 0.567134 Caregivers report 0.630818 Caregiver assessment 0.592589 family caregiver 0.60516 cancer patient 0.576832 difficult caregiver responsibilities 0.601191	CLICK HERE
1790	National Cancer Institute	Html	es	Trastornos del sueño (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de las causas y manejo de los trastornos del sueño en las personas con cáncer.	menudo causa problemas 0.738807 TCC ayuda 0.533662 pequeño número 0.542064 siguientes aspectos 0.690699 siguientes elementos 0.547894 leucemia linfocítica aguda 0.539982 sudores nocturnos 0.6269 siguientes cambios 0.544948 menor número 0.522208 Frecuencia respiratoria 0.534403 fase monr 0.549571 salud afectarán 0.52618 National Cancer Institute 0.522679	sueño mejora 0.68532 siguientes riesgos 0.520223 sueño mor 0.930755 Instituto Nacional 0.543079 siguientes problemas 0.588617 siguientes funciones 0.571878 Physician Data Query 0.591028 fase mor 0.552867 PDQ Trastornos 0.547079 auto hipnosis 0.530427 numerosas razones 0.546303 solo relajarme 0.534672	CLICK HERE
1830	National Cancer Institute	Html	es	Tratamiento de la leucemia mielógena crónica (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia mielógena crónica.	imatinib treatment 0.309815 associated with 0.307718 Saglio G 0.311488 Imatinib plus 0.308886 mayoría imatinib 0.309903 with chronic myeloid 0.371977 Sin embargo 0.315782 Kantarjian HM 0.372759 standard-dose imatinib therapy 0.309084 myeloid leukemia patients 0.32923 Cortes JE 0.313764 chronic myeloid leukemia 0.996248 or imatinib 0.327327 myelogenous leukemia patients 0.309285 Philadelphia chromosome-positive 0.307544 TCM alogénico 0.343658 chronic myelomonocytic leukemia 0.306491 patients with chronic 0.376511 Rosti G 0.305694 leucemia mielógena 0.3214 stem cell transplantation 0.309631 chronic myelogenous leukemia 0.537094 with imatinib 0.31893 Guilhot F 0.305867 vs imatinib 0.308365	Chronic Leukemia 0.308312 Versus Imatinib Study 0.318542 patients with philadelphia 0.308802 dasatinib or imatinib 0.311418 versus imatinib 0.331295 Jabbour E 0.308732 patients with 0.421072 myeloid leukemia treated 0.313347 Treatment-Naïve Chronic Myeloid 0.309823 marrow transplantation 0.313614 leukemia treated with 0.314928 Dasatinib Versus Imatinib 0.321251 bone marrow transplantation 0.310388 Leukemia Patients Trial 0.308496 newly diagnosed chronic 0.341689 treated with imatinib 0.310526 imatinib depends 0.308315 imatinib versus 0.310194 chronic granulocytic leukemia 0.306345 tirosina cinasa 0.443764 Clin Oncol 0.407181 bone marrow 0.312247 myelogenous leukemia with 0.307043 treated with 0.317153	CLICK HERE
2105	National Cancer Institute	Html	es	Exámenes de detección del cáncer de endometrio (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de endometrio.	Surgical Adjuvant Breast 0.318516 Obstet Gynecol 0.462808 endometrial neoplasia 0.330318 endometrial carcinoma 0.35462 mujeres asintomáticas conducirán 0.327753 endometrial biopsy 0.375747 Society Cancer Detection 0.324775 Sin embargo 0.322994 American Cancer Society 0.532275 Barakat RR 0.322448 postmenopausal estrogen 0.311047 Hereditary nonpolyposis colon 0.316803 Cancer Society Guidelines 0.326353 mutation analysis 0.309345 CA Cancer 0.344524 ecografía transvaginal 0.32543 Instituto Nacional 0.316776 PDQ Exámenes 0.310268 Natl Cancer Inst 0.409601 Vasen HF 0.314679 Bowel Project P-1 0.314149 Survival analysis 0.309166 endometrial thickness 0.328405 Gynecol Oncol 0.319248 patients with 0.312917	endometrial cancer 0.986652 Endometrial morphology 0.328059 Genetics Studies Consortium 0.313592 Cancer Facts 0.328027 Cancer risk 0.385512 with endometrial biopsy 0.334209 mutation carriers 0.308983 Cancer Survival Study 0.330775 hereditary nonpolyposis 0.373835 National Cancer Institute 0.323419 endometrial biopsy specimens 0.329768 replacement therapy 0.315579 postmenopausal women 0.352328 Clin Oncol 0.321066 Gynaecol Obstet 0.310774 PDQ Genetics 0.309874 mujeres portadoras 0.322212 adjuvant breast 0.320298 ecografía endovaginal 0.333573 endometrial abnormalities 0.37706 National Surgical Adjuvant 0.314342 Ultrasound Obstet Gynecol 0.310185 mujeres morirán 0.321645 Mecklin JP 0.317214	CLICK HERE
3523	National Cancer Institute	Html	es	Estudio NCI-MATCH (Análisis Molecular para Selección de Tratamientos)	Información sobre el estudio del NCI: Análisis Molecular para Selección de Tratamientos (NCI-MATCH), en el cual los investigadores examinarán tejidos de tumor de pacientes con tumores sólidos y linfomas avanzados que han dejado de responder al tratamiento.	Tumor Profiling 0.554625 estudio match 0.941659 Investigación Oncológica 0.6022 MD Anderson 0.61416 Memorial Sloan-Kettering Cancer 0.578519 Clinical Trials 0.539697 posibles participantes 0.607033 C2 MET 0.546519 Life Sciences 0.627896 laboratorios foundation medicine 0.56991 Foundation Medicine 0.623082 Memorial Sloan-Kettering identificarán 0.577406 estudio comet 0.807536 Grupo Cambio 0.537516 met amp crizotinib 0.576245	como los costos 0.539059 seguro médico 0.533808 Cancer Center 0.605302 MD Anderson Cancer 0.572606 tratamiento inscribirán 0.618222 sk crizotinib 0.541473 cabo estudios 0.534561 Caris Life Sciences 0.579205 Investigación Oncológica ECOG-ACRIN 0.571301 Memorial Sloan-Kettering 0.625566 egfr mut afatinib 0.573282 NRG Oncology Group 0.568484 Iniciativa de Medicina 0.538366 Life Sciences identificarán 0.57351	CLICK HERE
4394	National Cancer Institute	Html	null	Blue Ribbon Panel Working Groups	Seven working groups comprised of leading experts from the cancer community have been charged with developing recommendations for the Cancer Moonshot Initiative.			CLICK HERE
15802	National Cancer Institute	Html	null	About the Blue Ribbon Panel	Information about the Cancer Moonshot Blue Ribbon Panel of experts. The panel was established to ensure the Cancer Moonshot's goals and approaches are grounded in the best science.			CLICK HERE